Introduction to Malignant Pleural Effusions
Interventional pulmonologist Dr. Jed Gorden reviews malignant pleural effusions (MPEs) are a common complication of lung cancer and some other cancers. TranscriptSo, I wanted to talk to you today about pleural effusions. Pleural effusions — it's a complex term, and it's a very common problem, so let
Lung Cancer Video Library - Managing Malignant Pleural Effusions: Thoracentesis
Dr. Jed Gorden describes the details of how a thoracentesis is performed in order to clarify the diagnosis and treat symptoms of a malignant pleural effusion (MPE). TranscriptWith the pleural fluid that's built up around the lung — this fluid that exist in between the linings, or as we discussed
What is the Optimal Duration of Immunotherapy?
UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.
Immunotherapy for First Line Therapy of Advanced NSCLC
Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.
What Is Next-Gen Sequencing?
Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.
Lung Cancer Video Library - Blood-Based Mutation Testing: Circulating Tumor Cells and Tumor DNA
Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.
Lung Cancer Video Library - Different Lung Cancer Subtypes - Histology
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.
Lung Cancer Video Library - Can Serum Tumor Markers Be Used in the Management of Lung Cancer?
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.
SBRT as a Potential Alternative for Fit Patients with Early Stage Lung Cancer
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides evidence for the use of stereotactic body radiation therapy as an alternative to surgery for operable early stage lung cancer.
What is Stereotactic Radiosurgery/Radiation Therapy to the Brain or Body?
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the use of stereotactic radiosurgery and stereotactic radiation therapy.
SBRT for Medically Inoperable Stage I Lung Cancer
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation therapy for inoperable lung lesions.Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use
SBRT for Oligometastatic Lung Cancer
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
High vs. Standard Dose Chest Radiation in Stage III Lung Cancer
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.
What is V20 and Why Do Radiation Dose & Field Size Matter?
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.
Heterogeneity of Stage III NSCLC/Defining Resectability for Locally Advanced NSCLC
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.